A Bernardi, A C C V Zilberstein, E Jäger, M M Campos, F B Morrone, J B Calixto, A R Pohlmann, S S Guterres, A M O Battastini
BACKGROUND AND PURPOSE: The effects of systemic treatment with indomethacin-loaded nanocapsules (IndOH-NC) were compared with those of free indomethacin (IndOH) in rat models of acute and chronic oedema.
EXPERIMENTAL APPROACH: The following models of inflammation were employed: carrageenan-induced acute oedema (measured between 30 min and 4 h), sub-chronic oedema induced by complete Freund's adjuvant (CFA) (determined between 2 h and 72 h), and CFA-induced arthritis (oedema measured between 14 and 21 days).
KEY RESULTS: IndOH or IndOH-NC produced equal inhibition of carrageenan-elicited oedema. However, IndOH-NC was more effective in both the sub-chronic (33 +/- 4% inhibition) and the arthritis (35 +/- 2% inhibition) model of oedema evoked by CFA, when compared with IndOH (21 +/- 2% and 14 +/- 3% inhibition respectively) (P < 0.01). In the CFA arthritis model, treatment with IndOH-NC markedly inhibited the serum levels of the pro-inflammatory cytokines tumour necrosis factor alpha and IL-6 (by 83 +/- 8% and 84 +/- 11% respectively), while the levels of the anti-inflammatory cytokine IL-10 were significantly increased (196 +/- 55%). The indices of gastrointestinal damage in IndOH-NC-treated animals were significantly less that those after IndOH treatment (58 +/- 16%, 72 +/- 6% and 69 +/- 2%, for duodenum, jejunum and ileum respectively).
CONCLUSIONS AND IMPLICATIONS: IndOH-NC produced an increased anti-inflammatory efficacy in long-term models of inflammation, allied to an improved gastrointestinal safety. This formulation might represent a promising alternative for treating chronic inflammatory diseases, with reduced undesirable effects.
Eur J Pharmacol. 2008 May 31;586(1-3):24-34
[PMID:
18371953]
J Rheumatol. 1990 May;17(5):579-82
[PMID:
2359066]
Pharmacol Biochem Behav. 1988 Oct;31(2):445-51
[PMID:
3244721]
Neuroimmunomodulation. 2000;7(3):115-25
[PMID:
10754399]
Eur J Pharm Biopharm. 2003 Nov;56(3):501-5
[PMID:
14602195]
J Control Release. 2001 Jan 29;70(1-2):1-20
[PMID:
11166403]
Anesth Analg. 2005 Dec;101(6):1763-1769
[PMID:
16301256]
Adv Drug Deliv Rev. 1998 Dec 1;34(2-3):171-189
[PMID:
10837677]
Pharm Res. 2007 Oct;24(10):1944-53
[PMID:
17530389]
Inflamm Res. 2002 Mar;51(3):135-43
[PMID:
12005204]
Br J Pharmacol. 2006 Jul;148(5):688-95
[PMID:
16702985]
Drugs Aging. 2007;24(6):441-51
[PMID:
17571910]
Bull Acad Natl Med. 2003;187(5):935-54; discussion 954-5
[PMID:
14979058]
Int J Antimicrob Agents. 2000 Jan;13(3):155-68
[PMID:
10724019]
Curr Pharm Des. 2006;12(19):2349-63
[PMID:
16842183]
Curr Opin Rheumatol. 2003 Sep;15(5):623-7
[PMID:
12960491]
Trends Mol Med. 2005 Feb;11(2):56-63
[PMID:
15694867]
Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51
[PMID:
12204596]
Gut. 2008 Oct;57(10):1375-85
[PMID:
18467372]
Inflammopharmacology. 2005;13(4):343-70
[PMID:
16354389]
Pharm Res. 2006 May;23(5):873-81
[PMID:
16715377]
Pharmacol Ther. 2005 Aug;107(2):139-54
[PMID:
15993252]
Pharmazie. 2001 Nov;56(11):864-7
[PMID:
11817171]
Eur J Pharmacol. 2000 Jul 14;400(1):127-35
[PMID:
10913594]
J Rheumatol. 1999 Sep;26(9):2018-24
[PMID:
10493685]
Arthritis Rheum. 2006 Jun;54(6):1829-37
[PMID:
16729276]
J Pathol. 1973 Nov;111(3):149-58
[PMID:
4760142]
J Control Release. 2002 Jan 17;78(1-3):15-24
[PMID:
11772445]
Crit Rev Ther Drug Carrier Syst. 2002;19(2):99-134
[PMID:
12197610]
Cytokine. 2004 Nov 21-Dec 7;28(4-5):167-73
[PMID:
15588691]
Am J Physiol. 1992 May;262(5 Pt 1):G903-8
[PMID:
1317111]
Inflamm Res. 1997 Dec;46(12):509-14
[PMID:
9459082]
Dig Liver Dis. 2007 Dec;39(12):1043-51
[PMID:
17997373]
Neurol Res. 2007 Apr;29(3):324-30
[PMID:
17509234]
